New perspectives and strategy research biomarkers for hepatocellular carcinoma.


Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Cirrhosis caused by hepatitis B virus, hepatitis C virus or chronic alcohol intake is associated with major risk. Systematic screening for HCC of asymptomatic patients with cirrhosis is needed for earlier detection of small tumors requiring treatment (liver transplantation, surgical resection, percutaneous techniques). The recommended screening strategy among cirrhotic patients is based on regular liver ultrasonography associated with serum alpha-fetoprotein (AFP) assay. As the performance of AFP is not satisfactory, additional tumoral markers are proposed (des-gamma-carboxyprothrombin, glycosylated AFP-L3 fraction). Currently, diagnosis of HCC in cirrhotic patients includes non-invasive tests (imaging after contrast administration, AFP assay); diagnostic biopsy is performed when imaging is limited. After treatment, tumor recurrence is assessed by regular follow-up (AFP assay and imaging). Despite the lack of accurate markers, recent developments in genomic and proteomic approaches will allow the discovery of new biomarkers for primary tumors, as well as for recurrence. This review summarizes the current state of biomarkers for screening, diagnosis and follow-up of HCC, and highlights new perspectives in the field.

Citations per Year

140 Citations

Semantic Scholar estimates that this publication has 140 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Saffroy2007NewPA, title={New perspectives and strategy research biomarkers for hepatocellular carcinoma.}, author={Rapha{\"{e}l Saffroy and Patrick H. Pham and Ma{\^a}mar Reffas and Mohamed Takka and Antoinette Lemoine and Brigitte Debuire}, journal={Clinical chemistry and laboratory medicine}, year={2007}, volume={45 9}, pages={1169-79} }